Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11323275 | 1.00 | LMNA (0.51) | LMNASMN1; SMN2SLC1A3SLC1A1DPP8 | |
| SCHEMBL11414135 | 0.93 | HTT (0.53) | LMNASMN1; SMN2SLC1A3SLC1A1DPP8 | |
| SCHEMBL11414129 | 0.93 | HTT (0.53) | LMNASMN1; SMN2SLC1A3SLC1A1DPP8 | |
| SCHEMBL11310220 | 0.88 | LMNA (0.47) | LMNASMN1; SMN2DPP8DPP7HTT | |
| SCHEMBL11310223 | 0.88 | LMNA (0.47) | LMNASMN1; SMN2DPP8DPP7HTT | |
| SCHEMBL2138925 | 0.85 | LMNA (0.50) | LMNASMN1; SMN2SLC1A3SLC1A1DPP8 | |
| SCHEMBL11291906 | 0.85 | LMNA (0.50) | LMNASMN1; SMN2SLC1A3SLC1A1DPP8 | |
| SCHEMBL3462691 | 0.85 | LMNA (0.50) | LMNASMN1; SMN2SLC1A3SLC1A1DPP8 | |
| SCHEMBL334927 | 0.81 | SLC1A3 (0.64) | LMNASMN1; SMN2SLC1A3SLC1A1DPP8 | |
| SCHEMBL735799 | 0.81 | SLC1A3 (0.64) | LMNASMN1; SMN2SLC1A3SLC1A1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111481562-A | Application of apramycin in preparation of bacterial infectious disease treatment | 苏黎世大学 | 2020-08-04 | — | — | CN | disclosed |
| CN-111388489-A | Application of apramycin in preparation of bacterial infectious disease treatment | 苏黎世大学 | 2020-07-10 | — | — | CN | disclosed |
| US-9271993-B2 | Treatment of bacterial infectious diseases | UNIVERSITY OF ZURICH (CH) | 2016-03-01 | — | — | US | disclosed |
| EP-2616079-B1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | UNIV ZÜRICH (CH) | 2015-10-14 | — | — | EP | disclosed |
| EP-2616079-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | University of Zürich (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165397-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | ETH ZURICH (CH) | 2013-06-27 | — | — | US | disclosed |
| WO-2012034955-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | UNIVERSITY OF ZURICH (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-4284764-A | Process for the preparation of 5-fluoro-5-deoxy and 5-epi-fluoro-5-deoxy-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and novel 5-fluoro-5-deoxy and 5-epi-fluoro-5-deoxy derivatives produced thereby | SCHERING CORPORATION (US) | 1981-08-18 | — | — | US | disclosed |
| US-4029882-A | BACTERICIDES | SCHERING CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165397-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | APRT, BPGM, TLR5 | LMNA 2421/4885SMN1; SMN2 2461/4885SLC1A3 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.